Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Regeneron Pharmaceuticals: Clinical Trials & FDA Approval Profile

Regeneron Pharmaceuticals (Tarrytown, NY) sponsors 163 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 90 active protocols (54 recruiting now), 44 completed protocols, and 9 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.8%
Median Closed Enrollment vs National (145 pts)89 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Regeneron Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)163
Active Pipeline (Recruiting Now)90 (54)
Completed vs Stopped Early44 / 29 (17.8%)
Median Closed Actual Enrollment89 participants
Physical Hospital Site Disclosure99.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals9 (6 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Regeneron Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Samsung Medical CenterSeoul, Gangnam-Gu19
Seoul National University HospitalSeoul18
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA18

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Regeneron Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07430956Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePhase IIIRECRUITING
NCT06091865A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, iPhase IIIRECRUITING
NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of ChePhase IIIRECRUITING
NCT06140524A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult PatiePhase IIRECRUITING
NCT07626411Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Regeneron Pharmaceuticals Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI